Soluble ST2 and brain natriuretic peptide predict different mode of death in patients with heart failure and preserved ejection fraction
- 1 April 2019
- journal article
- research article
- Published by Elsevier in Journal of Cardiology
- Vol. 73 (4) , 326-332
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population With Heart Failure and Preserved Versus Reduced Ejection FractionJACC, 2012
- Prognostic Utility of ST2 in Patients with Acute Dyspnea and Preserved Left Ventricular Ejection FractionClinical Chemistry, 2011
- High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart FailureCirculation: Heart Failure, 2011
- Usefulness of Soluble Concentrations of Interleukin Family Member ST2 as Predictor of Mortality in Patients With Acutely Decompensated Heart Failure Relative to Left Ventricular Ejection FractionThe American Journal of Cardiology, 2011
- Establishment of reference intervals for soluble ST2 from a United States populationClinica Chimica Acta, 2010
- Pulmonary Hypertension in Heart Failure With Preserved Ejection FractionJACC, 2009
- Death in Heart FailureCirculation: Heart Failure, 2008
- Albumin levels predict survival in patients with systolic heart failureAmerican Heart Journal, 2008
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling systemJournal of Clinical Investigation, 2007
- B-Type Natriuretic Peptide Strongly Reflects Diastolic Wall Stress in Patients With Chronic Heart FailureJACC, 2006